Screener
CapEx at other companies
Other financials
Where this comes from
Reported directly by ARS Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: ARS Pharmaceuticals, Inc.’s 10-Q, filed May 15, 2026.
- Filed
- May 15, 2026, 6:17 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-225142
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Cash flows from investing activities: | ||
| Purchases of short-term investments, available-for-sale | (14,709) | (34,345) |
| Maturities of short-term investments, available-for-sale | 42,500 | 63,500 |
| Purchases of property and equipment | — | (91) |
| Net cash and cash equivalents provided by investing activities | 27,791 | 29,064 |
| Cash flows from financing activities: | ||
| Proceeds from royalties earned under license agreements recognized as an increase to the financing liability | 97 | — |
| Proceeds from exercise of common stock options and issuance of common stock under the employee stock purchase plan | 62 | 725 |
Item 1. Financial Statements
FAQ
- What is ARS Pharmaceuticals, Inc.'s capex?
- ARS Pharmaceuticals, Inc. (SPRY) reported capex of $0 in Q1 2026.
- How has ARS Pharmaceuticals, Inc.'s capex changed year-over-year?
- ARS Pharmaceuticals, Inc.'s capex decreased by 100.0% year-over-year, from $91K to $0.
- What is the long-term trend for ARS Pharmaceuticals, Inc.'s capex?
- Over 2 years (2022 to 2025), ARS Pharmaceuticals, Inc.'s capex has grown at a 30.5% compound annual growth rate (CAGR), from $199K to $339K.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about ARS Pharmaceuticals, Inc.'s capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude